Crystal Kizarr, APRN
Family · Duncan, OKNPI 1053661181
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,155 of the $4,740 with a category attached, or 87.6%. It is spread thinly across 50 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$693
- Johnson & Johnson$409
- Lilly USA, LLC$333
- Incyte Corporation$328
- AstraZeneca$285
- Merck$250
- plus $2K from 44 others
What the payments were for
- Food & beverage$4,15588%
- Education$58612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,740 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 115 | $6,100 |
| Exemestane | 20 | $1,152 |
| Anastrozole | 33 | $654 |
| Ondansetron OdtOndansetron | 40 | $550 |
| Levothyroxine Sodium | 66 | $475 |
| Dexamethasone | 21 | $360 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 30 | $340 |
| Prochlorperazine Maleate | 30 | $316 |
| Acyclovir | 42 | $303 |
| Omeprazole | 11 | $235 |
| Tamoxifen Citrate | 11 | $182 |
| Prednisone | 32 | $168 |
| Pentoxifylline | 11 | $157 |
| Gabapentin | 31 | $157 |
| Famotidine | 16 | $98 |
Paid to pharmacies, not to this prescriber.
Other family in Duncan
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
- Kristina SnyderOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.